Background: Relationship changes after cancer are prevalent yet underexplored. This investigation aimed to assess factors influencing relationship changes between participants receiving the 2 most common gender-specific cancer diagnoses: breast and prostate.
Methods: Anonymous surveys were administered via Amazon Mechanical Turk. Eligible participants were 18 years or older and diagnosed with breast or prostate cancer. Relationship satisfaction and mental health were assessed via Personal Health Questionnaire Depression Scale (PHQ-8), General Anxiety Disorder (GAD-7), and Self-Esteem and Relationship Questionnaire.
Results: Of the 186 study respondents, 85.4% (159) had breast cancer and 14.5% (27) had prostate cancer. More breast cancer participants reported that their relationship worsened after cancer diagnosis (breast: 40.9%, prostate: 11.1%), whereas a majority of prostate cancer patients reported improved relationships (breast: 17%, prostate: 66.7%; < 0.001). However, most participants reported no relationship status change (breast: 66.7%, prostate: 77.8%; = 0.508) and remained with the same partner postdiagnosis (breast: 84.9%; prostate: 77.8%). Breast cancer participants reported higher self-esteem compared with prostate cancer participants ( = 0.019). There was no significant difference in overall Self-Esteem and Relationship Questionnaire ( = 0.140), PHQ-8 ( = 0.689), and GAD-7 ( = 0.871) scores. Average PHQ-8 and GAD-7 scores indicated moderate depression (breast: 12.62, prostate: 12.88) and moderate anxiety (breast: 10.96, prostate: 11.06).
Conclusions: Breast cancer participants reported greater perceived changes in their relationship postdiagnosis. This study supports routine, active, and pre-emptive involvement of a mental health provider for patients with cancer to improve mental health outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845180 | PMC |
| http://dx.doi.org/10.1097/GOX.0000000000006494 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area Deprivation Index on Initial Treatment Type for Localized PCa in a North-American Cohort.
Prostate
March 2025
VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, Michigan, USA.
Background: Socioeconomic status and geographical location contribute to disparities in localized prostate cancer (PCa) treatment. We examined the impact of area of deprivation index (ADI) on initial treatment type for localized PCa in a North-American cohort.
Methods: We performed a retrospective analysis of patients diagnosed with localized PCa, treated within Henry Ford Health (HFH), between 1995 and 2022, with available ADI-data.
Background And Objective: Prostate cancer (PCa) is a significant global health concern, ranking as the second most prevalent cancer among men worldwide. Genetic factors, particularly germline pathogenic variants (PVs) in DNA repair genes (DRGs), play a crucial role in PCa predisposition. Our study aimed to assess patients' adherence to a targeted PCa screening program targeting high-risk individuals with DRG PVs and evaluate the potential reduction in biopsy and MRI rates by employing our screening protocol.
View Article and Find Full Text PDFCepharanthine hydrochloride: a novel ferroptosis-inducing agent for prostate cancer treatment.
Front Pharmacol
February 2025
Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, China.
Background: Ferroptosis is an intracellular iron-dependent cell death that is distinct from apoptosis, necrosis, and autophagy. Increasing evidence indicated that ferroptosis plays a crucial role in suppressing tumors, thus providing new opportunities for cancer therapy. The drug cepharanthine, commonly used to treat leukopenia, has been discovered to function as an anticancer agent to multiple types of cancer via diverse mechanisms.
View Article and Find Full Text PDFoncology: a mechanistic multiscale model of clinical prostate cancer response to external radiation therapy as the core of a digital (virtual) twin. Sensitivity analysis and a clinical adaptation approach.
Front Physiol
February 2025
German Cancer Consortium (DKTK), Partner Site Freiburg, Heidelberg, Germany.
Introduction: Prostate cancer (PCa) is the most frequent diagnosed malignancy in male patients in Europe and radiation therapy (RT) is a main treatment option. However, current RT concepts for PCa have an imminent need to be rectified in order to modify the radiotherapeutic strategy by considering (i) the personal PCa biology in terms of radio resistance and (ii) the individual preferences of each patient.
Methods: To this end, a mechanistic multiscale model of prostate tumor response to external radiotherapeutic schemes, based on a discrete entity and discrete event simulation approach has been developed.
Hyperactivation of fatty acid biosynthesis holds promise as a targeted therapeutic strategy in prostate cancer (PCa). However, inhibiting these enzymes could potentially promote metastatic progression in various other cancers. Herein, we found that depletion of acetyl-CoA carboxylase 1 (encoded by ACACA), the enzyme responsible for the first and rate-limiting step of de novo fatty acid biosynthesis, facilitated epithelial-mesenchymal transition (EMT) and migration of PCa cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!